PolypDx uses a proprietary technology platform to detect adenomatous polyps. The test uses metabolite biomarkers to detect polyps before they become malignant.
“PolypDx can be integrated into the diagnostic process for colon cancer and lowers the overall costs incurred by a patient who would otherwise have to undergo a colonoscopy just to assess polyp presence,” said Frost & Sullivan Research Analyst Madhumitha Rangesa.
More articles on gastroenterology:
Dr. Nitesh Ratnakar elected West Virginia ACG governor
5 gastroenterologists leadership moves
5 statistics on gastroenterologist compensation, career satisfaction
